Circulatory and other-cause mortality after neoadjuvant versus adjuvant chemotherapy in women with stage II-III breast cancer.
In older long-term breast-cancer survivors, late mortality is predominantly multimorbid rather than circulatory-dominant, supporting survivorship care that addresses cardiovascular risk within a broader framework of age-related competing health risks.